News
Strapped stem cell agency eyes tough options
Robert Klein addresses a meeting of two governing board committees of the California Institute for Regenerative Medicine. (Photo: David Jensen, California Stem Cell Report)Facing the likelihood of a slow and withering death, the California stem cell agency is edging gingerly forward on a path of “cuts” and risky fund-raising in hopes that its research results will soon generate voter support for more billions of dollars. Two governing board committees of the $3 billion agency, formally known as the California Institute for Regenerative Medicine (CIRM), on Monday. Nov. 27, recommended that the full board “entertain” the proposals at its Dec. 14 meeting.